Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma

References

• Aviv A, Tadmor T, Polliack A. Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol. 2013;24(9):2236–2244. doi:10.1093/annonc/mdt192. Epub 2013/05/29. PubMed PMID: 23712546.
   PubMed Web of Science ®Google Scholar
• Peng F, Li J, Mu S, et al. Epidemiological features of primary breast lymphoma patients and development of a nomogram to predict survival. The Breast. 2021;57:49–61. doi:10.1016/j.breast.2021.03.006. PubMed PMID: 33774459; PubMed Central PMCID: PMCPMC8027901.
   PubMed Web of Science ®Google Scholar
• Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer. 1972;29(6):1705–1712. doi:10.1002/1097-0142(197206)29:6 < 1705::aid-cncr2820290640 > 3.0.co;2-i. Epub 1972/06/01. PubMed PMID: 4555557.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Sakai R, Sakuma T, et al. Comparison of clinical features between primary and secondary breast diffuse large B cell lymphoma: a yokohama cooperative study group for hematology multicenter retrospective study. Indian J Hematol Blood Transfusion. 2021;37(1):60–66. doi:10.1007/s12288-020-01307-7. PubMed PMID: 33707836; PubMed Central PMCID: PMCPMC7900317.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhao H, Cui Z, et al. A multicentre retrospective study of primary breast diffuse large B-cell and high-grade B-cell lymphoma treatment strategies and survival. Hematology (Amsterdam, Netherlands). 2020;25(1):203–210. doi:10.1080/16078454.2020.1769419. Epub 2020/06/02. PubMed PMID: 32476626.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Ryan G, Seymour JF, et al. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2009;20(12):1993–1999. doi:10.1093/annonc/mdp238. Epub 2009/07/03. PubMed PMID: 19570964.
   PubMed Web of Science ®Google Scholar
• Lalani N, Winkfield KM, Soto DE, et al. Management and outcomes of women diagnosed with primary breast lymphoma: a multi-institution experience. Breast Cancer Res Treat. 2018;169(1):197–202. doi:10.1007/s10549-018-4671-8. Epub 2018/01/23. PubMed PMID: 29356916.
   PubMed Web of Science ®Google Scholar
• Uesato M, Miyazawa Y, Gunji Y, et al. Primary non-hodgkin’s lymphoma of the breast: Report of a case with special reference to 380 cases in the Japanese literature (Tokyo, Japan). Breast Cance. 2005;12(2):154–158. doi:10.2325/jbcs.12.154. Epub 2005/04/29. PubMed PMID: 15858449.
   PubMedGoogle Scholar
• Zhang N, Cao C, Zhu Y, et al. Primary breast diffuse large B-cell lymphoma in the era of rituximab. Onco Targets Ther. 2016;9:6093–6097. doi:10.2147/OTT.S108839. PubMed PMID: 27785056; PubMed Central PMCID: PMCPMC5065257.
   PubMed Web of Science ®Google Scholar
• Ou CW, Shih LY, Wang PN, et al. Primary breast lymphoma: a single-institute experience in Taiwan. Biomed J. 2014;37(5):321–325. doi:10.4103/2319-4170.132889. Epub 2014/09/03. PubMed PMID: 25179707.
   PubMedGoogle Scholar
• Aviles A, Neri N, Nambo MJ. The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast. Am J Clin Oncol. 2012;35(2):126–129. doi:10.1097/COC.0b013e318209aa12. Epub 2011/02/18. PubMed PMID: 21325938.
   PubMed Web of Science ®Google Scholar
• Kuper-Hommel MJ, Snijder S, Janssen-Heijnen ML, et al. Treatment and survival of 38 female breast lymphomas: a population-based study with clinical and pathological reviews. Ann Hematol. 2003;82(7):397–404. doi:10.1007/s00277-003-0664-7. Epub 2003/05/24. PubMed PMID: 12764549.
   PubMed Web of Science ®Google Scholar
• Kewan T, Covut F, Ahmed R, et al. Clinical characteristics and outcomes of primary breast lymphoma: The Cleveland clinic experience. Cureus. 2020;12(6):e8611, doi:10.7759/cureus.8611. PubMed PMID: 32676248; PubMed Central PMCID: PMCPMC7362621.
   PubMed Web of Science ®Google Scholar
• Pérez F F, Lavernia J, Aguiar-Bujanda D, et al. Primary breast lymphoma: analysis of 55 cases of the spanish lymphoma oncology group. Clin Lymphoma Myeloma Leukemia. 2017;17(3):186–191. doi:10.1016/j.clml.2016.09.004. Epub 2016/11/17. PubMed PMID: 27847267.
   PubMed Web of Science ®Google Scholar
• Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2008;19(2):233–241. doi:10.1093/annonc/mdm471. Epub 2007/10/13. PubMed PMID: 17932394.
   PubMed Web of Science ®Google Scholar
• Jennings WC, Baker RS, Murray SS, et al. Primary breast lymphoma. Ann Surg 2007;245(5):784–789. doi:10.1097/01.sla.0000254418.90192.59. PubMed PMID: 17457172; PubMed Central PMCID: PMCPMC1877073.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang Y, Fei H, et al. Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience. Cancer Cell Int. 2021;21(1):498, doi:10.1186/s12935-021-02198-y. PubMed PMID: 34535141; PubMed Central PMCID: PMCPMC8447786.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569. PubMed PMID: 26980727; PubMed Central PMCID: PMCPMC4874220.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545. Epub 2003/09/25. PubMed PMID: 14504078.
   PubMed Web of Science ®Google Scholar
• Yhim HY, Kang HJ, Choi YH, et al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer. 2010;10:321, doi:10.1186/1471-2407-10-321. PubMed PMID: 20569446; PubMed Central PMCID: PMCPMC2927999.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407. doi:10.1056/NEJMoa1801445. PubMed PMID: 29641966; PubMed Central PMCID: PMCPMC6010183.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021–4031. doi:10.1182/blood-2012-10-460063. quiz 250. PubMed PMID: 23449635; PubMed Central PMCID: PMCPMC3709650.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–4126. doi:10.1200/JCO.2005.09.131. Epub 2005/05/04. PubMed PMID: 15867204.
   PubMed Web of Science ®Google Scholar
• Henry-Amar M, Friedman S, Hayat M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. Ann Intern Med. 1991;114(5):361–365. doi:10.7326/0003-4819-114-5-361. Epub 1991/03/01. PubMed PMID: 1992877.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800. PubMed PMID: 25113753; PubMed Central PMCID: PMCPMC4979083 are found at the end of this article.
   PubMed Web of Science ®Google Scholar
• Luo B, Huang J, Yan Z, et al. Clinical and prognostic analysis of 21 cases of primary breast lymphoma. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2015;36(4):277–281. doi:10.3760/cma.j.issn.0253-2727.2015.04.003. Epub 2015/04/29. PubMed PMID: 25916285; PubMed Central PMCID: PMCPMC7342608.
   PubMedGoogle Scholar
• Hu S, Song Y, Sun X, et al. Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure. Cancer Sci. 2018;109(12):3943–3952. doi:10.1111/cas.13828. PubMed PMID: 30302857; PubMed Central PMCID: PMCPMC6272095.
   PubMed Web of Science ®Google Scholar
• Jeong H, Cho H, Kim H, et al. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis. Blood Adv. 2021;5(8):2142–2152. doi:10.1182/bloodadvances.2020003947. PubMed PMID: 33881464; PubMed Central PMCID: PMCPMC8095148 interests.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Nickelsen M, et al. Cns international prognostic index: A risk model for CNS relapse in patients With diffuse large B-cell lymphoma treated With R-CHOP. J Clin Oncol. 2016;34(26):3150–3156. doi:10.1200/JCO.2015.65.6520. Epub 2016/07/07. PubMed PMID: 27382100.
   PubMed Web of Science ®Google Scholar